世界中医药

目的：探讨黄葵胶囊联合还原型谷胱甘肽(GSH)在糖尿病肾病中的应用效果。方法：选取2016年2月至2017年1月江苏省无锡市第三人民医院收治的糖尿病肾病患者128例，按照随机数字表法分为对照组与观察组，每组64例。对照组患者给予GSH静脉滴注，观察组患者则在此基础上加用黄葵胶囊联合治疗，通过观察治疗前后血糖、血脂、肾功能判定疗效，监测用药前后血清γ-谷氨酰转肽酶（GGT）、晚期糖基化终末产物(AOPP)、白介素-1β（IL-1β）水平。结果：观察组的临床疗效高达90.6%，与对照组的76.6%比较升高显著（P<0.05）；治疗后观察组患者的血糖、血脂、肾功能显著低于治疗前及对照组（P<0.05）；治疗后观察组的GGT、AOPP、IL-1β低于治疗前及对照组（P<0.05）。结论：黄葵胶囊联合GSH利于控制血糖，调节脂质代谢紊乱，改善肾功能，疗效理想，其机制可能与调控血清中GGT、AOPP、IL-1β水平以减轻机体的氧化应激损伤、微炎性反应状态密切相关。

English Summary:

To study the effectiveness of Huangkui capsule and GSH in treating diabetic nephropathy.Methods:A total of 128 patients with diabetic nephropathy who were admitted and treated in our hospital from February 2016 to January 2017 were randomly divided into control group of 64 cases and observation group of 64 cases.Patients in the control group were treated with GSH, while patients in the observation group were given Huangkui capsule and GSH.The effectiveness was determined by observing the changes of blood sugar, blood fat and kidney function, and monitoring the changes of GGT, AOPP and IL-1β level.Results:The clinical efficiency for patients in the observation group was 90.6%, which was higher than 76.6% in the control group (P<0.05); The indexes of blood sugar, blood fat and kidney function for patients in the observation group were lower than that of the control group (P<0.05); The levels of GGT, AOPP and IL-1β for patients in the observation group were lower than that of the control group after treatment (P<0.05).Conclusion:Huangkui capsule and GSH are good in controlling blood glucose, lipid metabolic disorder and improving renal function, with satisfactory clinical effects.The mechanism may be associated with regulating the levels of GGT, AOPP and IL-1β to reduce the body state of oxidative stress damage, micro inflammation reaction, which is worthy of clinical promotion.

查看全文查看/发表评论下载PDF阅读器